board WHOcte. Soft tissue and bone tumours. 5th ed. World Health Organization classification of tumours. World Health Organization. International Agency for Research on Cancer; 2020.

Nagano A, Urakawa H, Tanaka K, Ozaki T. Current management of giant-cell tumor of bone in the denosumab era. Jpn J Clin Oncol. 2022;52(5):411–6. https://doi.org/10.1093/jjco/hyac018.

Article  PubMed  Google Scholar 

Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37(1):35–51. https://doi.org/10.1016/j.ocl.2005.08.005.

Article  PubMed  Google Scholar 

Rekhi B, Dave V. Giant cell tumor of bone: an update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses. Histol Histopathol. 2023;38(2):139–53. https://doi.org/10.14670/hh-18-486.

Article  CAS  PubMed  Google Scholar 

Basu Mallick A, Chawla SP. Giant cell tumor of bone: an update. Curr Oncol Rep. 2021;23(5):51. https://doi.org/10.1007/s11912-021-01047-5.

Article  CAS  PubMed  Google Scholar 

Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, et al. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020;33(4):1321–8. https://doi.org/10.1007/s13577-020-00415-w.

Article  CAS  PubMed  Google Scholar 

Yamamoto H, Ishihara S, Toda Y, Oda Y. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Med Mol Morphol. 2020;53(1):1–6. https://doi.org/10.1007/s00795-019-00238-1.

Article  CAS  PubMed  Google Scholar 

Taylor EL, Westendorf JJ. Histone mutations and bone cancers. Adv Exp Med Biol. 2021;1283:53–62. https://doi.org/10.1007/978-981-15-8104-5_4.

Article  CAS  PubMed  Google Scholar 

Yang L, Zhang H, Zhang X, Tang Y, Wu Z, Wang Y, et al. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): analysis of 21 cases. Ann Diagn Pathol. 2022;57: 151882. https://doi.org/10.1016/j.anndiagpath.2021.151882.

Article  PubMed  Google Scholar 

Li H, Gao J, Gao Y, Lin N, Zheng M, Ye Z. Denosumab in giant cell tumor of bone: current status and pitfalls. Front Oncol. 2020;10: 580605. https://doi.org/10.3389/fonc.2020.580605.

Article  PubMed  PubMed Central  Google Scholar 

Lin X, Liu J, Xu M. The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis. Transl Cancer Res. 2021;10(4):1712–22. https://doi.org/10.21037/tcr-20-3100.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol. 2017;7:23–8. https://doi.org/10.1016/j.jbo.2017.04.001.

Article  PubMed  PubMed Central  Google Scholar 

Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat. 2019;18:1533033819840000. https://doi.org/10.1177/1533033819840000.

Article  PubMed  Google Scholar 

Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol. 2014;12:261. https://doi.org/10.1186/1477-7819-12-261.

Article  PubMed  PubMed Central  Google Scholar 

Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL. A High-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res. 2015;473(9):3050–5. https://doi.org/10.1007/s11999-015-4249-2.

Article  PubMed  PubMed Central  Google Scholar 

Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2021;112(3):953–61. https://doi.org/10.1111/cas.14669.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hattori E, Oyama R, Kondo T. Systematic review of the current status of human sarcoma cell lines. Cells. 2019;8(2):157. https://doi.org/10.3390/cells8020157.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14(1):3–13. https://doi.org/10.1158/1541-7786.Mcr-15-0189.

Article  CAS  PubMed  Google Scholar 

Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25–38. https://doi.org/10.7171/jbt.18-2902-002.

Article  PubMed  PubMed Central  Google Scholar 

Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140(5):1209–14. https://doi.org/10.1002/ijc.30530.

Article  CAS  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, Tsuchiya R, Sin Y, Nakagawa R, et al. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022;35(1):392–9. https://doi.org/10.1007/s13577-021-00639-4.

Article  CAS  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023;36(5):1804–12. https://doi.org/10.1007/s13577-023-00928-0.

Article  CAS  PubMed  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Sin Y, Akane S, et al. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2021;34(6):1899–910. https://doi.org/10.1007/s13577-021-00579-z.

Article  CAS  PubMed  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, et al. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Hum Cell. 2022;35(5):1621–9. https://doi.org/10.1007/s13577-022-00724-2.

Article  CAS  PubMed  Google Scholar 

Gonçalves E, Poulos RC, Cai Z, Barthorpe S, Manda SS, Lucas N, et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell. 2022;40(8):835-49.e8. https://doi.org/10.1016/j.ccell.2022.06.010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinker GS, Greenwald AC, Tal R, Orlova Z, Cuoco MS, McFarland JM, et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat Genet. 2020;52(11):1208–18. https://doi.org/10.1038/s41588-020-00726-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016;17(Suppl 7):525. https://doi.org/10.1186/s12864-016-2911-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karpik M. Giant cell tumor (tumor gigantocellularis, osteoclastoma)—epidemiology, diagnosis, treatment. Ortop Traumatol Rehabil. 2010;12(3):207–15.

MathSciNet  PubMed  Google Scholar 

Lim J, Park JH, Baude A, Yoo Y, Lee YK, Schmidt CR, et al. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. Sci Rep. 2017;7(1):13459. https://doi.org/10.1038/s41598-017-13887-y.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Jeon H. 3D cell cultures toward quantitative high-throughput drug screening. Trends Pharmacol Sci. 2022;43(7):569–81. https://doi.org/10.1016/j.tips.2022.03.014.

Article  CAS  PubMed  Google Scholar 

Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–24. https://doi.org/10.1038/nprot.2008.226.

Article  CAS  PubMed  Google Scholar 

Shimony S, Horowitz N, Ribakovsky E, Rozovski U, Avigdor A, Zloto K, et al. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: real-life data from a national multicenter observational study. Hematol Oncol. 2019;37(5):569–77. https://doi.org/10.1002/hon.2691.

Article  CAS  PubMed  Google Scholar 

Venneker S, van Eenige R, Kruisselbrink AB, Palubeckaitė I, Taliento AE, Briaire-de Bruijn IH, et al. Histone deacetylase inhibitors as a therapeutic strategy to eliminate neoplastic “stromal” cells from giant cell tumors of bone. Cancers (Basel). 2022;14(19):4708. https://doi.org/10.3390/cancers14194708.

Article  CAS  PubMed  Google Scholar 

Yafei J, Haoran M, Wenyan J, Linghang X, Kai T, Gangyang W, et al. Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation. J Orthop Translat. 2021;29:106–12. https://doi.org/10.1016/j.jot.2021.04.004.

Article